Phase 3
N=322
Nicotine Mouth Film for Craving Relief.
Smoking Cessation
Bottom Line
View on ClinicalTrials.gov: NCT01702532 ↗Enrolled (actual)
322
Serious AEs
0.0%
Results posted
Jan 2014
Primary outcome: Primary: The Change From Pre-dose Post-provocation in Craving Score at 50 Seconds — -14.15; -9.26 mm — p=0.0141
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Nicotine (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- GlaxoSmithKline
- Primary completion
- Dec 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Change From Pre-dose Post-provocation in Craving Score at 50 Seconds |
-14.15; -9.26 | 0.0141 sig |
| SECONDARY The Change From Pre-dose Post-provocation in Craving Score at 3, 5, 7, 10, 15, 20, 25, and 30 Minutes |
-27.02; -20.30; -33.95; -28.33; -39.13; -34.14 | — |
Summary
Nicotine mouth film is a new dosage form of nicotine replacement therapy. The purpose of this study is to investigate the craving relief efficacy of nicotine mouth film by comparing mint nicotine mouth film to nicotine lozenge in light smokers using the provoked craving model. The cues used to provoke a craving episode will be the sight and smell of a lit cigarette and the manipulations required to light a cigarette. The smokers will be denied access to cigarettes for 4 hours prior to the provoked craving session in order to precipitate nicotine withdrawal and an increase level of cigarette craving.
Eligibility Criteria
Inclusion Criteria
- BMI within the range of 19-35 kg/m2;
- Current cigarette smokers who have smoked regularly daily for at least a year,
- Participants who smoke their first cigarette more than 30 minutes after waking up
Exclusion Criteria
- Known or suspected intolerance or hypersensitivity to nicotine (or closely related compounds) or any of the stated ingredients in formulation.
- Any participant whose CO level rises during the sequestration period (i.e., the subject's two expired CO assessments immediately prior to the provoked craving paradigm are higher than the mean baseline CO assessment) and, in the opinion of the investigator, may have smoked during that time.
Data sourced from ClinicalTrials.gov (NCT01702532). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.